title: Citalopram: new indication. No advantage.
abstract: (1) Citalopram, a serotonin reuptake inhibitor antidepressant, now has a new licensed indication, in the preventive treatment of panic attacks.  In France, clomipramine, a tricyclic antidepressant, and paroxetine, another serotonin reuptake inhibitor, are already approved for this use.  (2) In the only available comparative trial the efficacy of citalopram (20-60 mg/day) was similar to that of clomipramine (60-90 mg/day).  (3) The safety profile of citalopram is different from that of clomipramine.  (4) There are no data clearly comparing citalopram with paroxetine in terms of efficacy, safety, drug interactions, or convenience.  (5) Clomipramine is much cheaper than citalopram.
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D016584:Panic Disorder / Q000188:drug therapy*; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D002997:Clomipramine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors